← Leaderboards
Saraswati Pokharel
Roswell Park Cancer Institute Corp
$2,991,124
Attributed
$2,991,124
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $629.8K · FY2018–25$1M$750K$500K$250K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,991,124 · 3
By mechanism
R01$2,050,609 · 1
R21$940,515 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Serum”
- James Dale Berry · Brigham And Women'S Hospital$25,017,559
- Maria C Carrillo · Indiana University Indianapolis$19,445,642
- Amit Singal · Ut Southwestern Medical Center$13,798,031
- Leonard Freedman · Leidos Biomedical Research, Inc.$12,916,531
- Quy Phung · Leidos Biomedical Research, Inc.$12,889,396
- Xinhua Li · Nano Terra, Inc.$11,941,250
Research focus
SerumLiposomesNovel TherapeuticsCellsProtocols DocumentationPreventMyocardialTissuesMediatingFibrosisOrganChestIn VivoPeptidesLeadHeart FunctionIncidenceMalignant Neoplasm Of LungHeart FailureMouse ModelCardiacMalignant NeoplasmsLoss Of FunctionCytotoxic
Grant awards (9)
Inhibition of Radiation-Induced Coronary Microvascular Disease$411,136
R01 · FY2025 · HL · contact PI
Inhibition of Radiation-Induced Coronary Microvascular Disease$403,093
R01 · FY2024 · HL · contact PI
Inhibition of Radiation-Induced Coronary Microvascular Disease$403,365
R01 · FY2023 · HL · contact PI
Inhibition of Radiation-Induced Coronary Microvascular Disease$412,515
R01 · FY2022 · HL · contact PI
Inhibition of Radiation-Induced Coronary Microvascular Disease$420,500
R01 · FY2021 · HL · contact PI
Early Detection and Immunomodulation of PD-1 Inhibitor Induced Cardiotoxicity$209,275
R21 · FY2021 · HL · contact PI
Early Detection and Immunomodulation of PD-1 Inhibitor Induced Cardiotoxicity$258,790
R21 · FY2020 · HL · contact PI
Liposomal Delivery of a Novel Peptide N-acetyl-Ser-Asp-Lys-Pro to Inhibit Cancer Radiotherapy-Induced Cardiac Damage$214,750
R21 · FY2019 · HL · contact PI
Liposomal Delivery of a Novel Peptide N-acetyl-Ser-Asp-Lys-Pro to Inhibit Cancer Radiotherapy-Induced Cardiac Damage$257,700
R21 · FY2018 · HL · contact PI